Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer.
about
Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV.The role of human papillomavirus in oral carcinogenesis.Validation of Serological Antibody Profiles Against Human Papillomavirus Type 16 Antigens as Markers for Early Detection of Cervical Cancer.Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global reviewThe epidemiology of conjunctival squamous cell carcinoma in UgandaHuman papillomavirus types in invasive cervical cancer worldwide: a meta-analysisSpecificity of L1 peptides versus virus-like particles for detection of human papillomavirus-positive cervical lesions in females attending Engativa Hospital, Bogota, ColombiaPrevalence of serum antibodies to human papilloma virus in patients with genital ulcer disease in an urban population of Tanzania.Human papillomavirus types 16 and 18 DNA load in relation to coexistence of other types, particularly those in the same species.Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer.Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.Genotyping of human papillomavirus in paraffin embedded cervical tissue samples from women in Ethiopia and the Sudan.Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.Prevalence of human papillomavirus infection in women in Busan, South Korea
P2860
Q33905022-74A25ED0-7FD1-4B9F-8B9F-AF6DED076FC9Q35850833-7D058F64-1B32-4C55-8545-1201569EB93CQ36581107-F5516CB5-43F4-4E6B-AA94-F7FA7EA4870BQ36609068-9033E225-1BEA-4A72-91ED-7A94D32B90C9Q36624010-A3261812-9057-4510-9231-77983C085247Q36647828-5AA6C65E-FCBF-44D8-B167-82745CB1A96FQ36957928-402D56F0-6B59-4647-9F30-0C9FE8EF1821Q37006035-C4AA1661-D06D-43B4-8680-110BE3D2B9FBQ37349373-EB6628F9-B6FC-44B8-88F7-CD162C7970C7Q39683911-4DA16E04-1CCD-4F10-BA33-83DF32BF8E45Q42224757-FC9B29A6-F64C-4ECA-B62D-57A89FF97857Q42273331-B43550A1-6684-4DB5-A5B9-6D56B2A3A396Q43454820-6E10EC01-C450-48EA-928C-A76402D9A8C7Q44280889-9FA92C23-D687-49FD-ADE2-FBA8B8582168Q57216236-1E32D292-D61C-47AE-A064-A87F298F92BD
P2860
Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Serologic response to human on ...... with invasive cervical cancer.
@en
Serologic response to human on ...... with invasive cervical cancer.
@nl
type
label
Serologic response to human on ...... with invasive cervical cancer.
@en
Serologic response to human on ...... with invasive cervical cancer.
@nl
prefLabel
Serologic response to human on ...... with invasive cervical cancer.
@en
Serologic response to human on ...... with invasive cervical cancer.
@nl
P2093
P2860
P356
P1476
Serologic response to human on ...... with invasive cervical cancer.
@en
P2093
Alba-Lucia Combita
Antoine Touzé
Maria-Mercedes Bravo
Oscar Orozco
Pierre Coursaget
P2860
P304
P356
10.1002/IJC.10153
P577
2002-02-01T00:00:00Z